6
Oct
2022

Nobel for Bertozzi, Red Tree Eyes West Coast, & Doubling Down on Singapore

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Vigil, Inozyme Acquired, Prime Cuts, & Regeneron Scoops Up 23andMe
Genentech’s Bet on NC, GSK Buys Boston Liver Drug, & Septerna Entices Novo
NewLimit’s Anti-Aging Bounty, a Twist Spinout, & AI Coming to the FDA
FDA in Crisis, Parker Institute Snags Big Fish, & Merida Megaround